[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, nintedanib has shown promise for the treatment of lung disease associated with systemic sclerosis. Document [0] states that nintedanib interferes at multiple critical steps in the pathobiology of systemic sclerosis-associated interstitial lung disease, providing a convincing rationale for its investigation as a potential therapy. Document [1] mentions that nintedanib received marketing approval in the United States and Japan for the treatment of systemic sclerosis-associated interstitial lung disease based on positive results from a phase III clinical trial. Document [9] further supports this by stating that nintedanib has been shown to have antifibrotic and anti-inflammatory effects in preclinical models of systemic sclerosis and interstitial lung disease. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]